Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER’s Long Goodbye: Biologics Approval Time Jumps To 30 Months In 2002

Executive Summary

The average approval time for new biologic therapeutics and vaccines in 2002 was 30.1 months, an 11-month increase from 2001

You may also be interested in...



Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?

Pfizer's product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon

Pfizer Could Launch Three Significant NMEs in 2004; Will Any Surpass Viagra?

Pfizer's product outlook is brightening in 2004, with the launch of three commercially significant new molecular entity products on the horizon

Baxter/Alpha Aralast Launch Will Ease Bayer Prolastin Supply Pressure

Baxter/Alpha Therapeutics' Aralast alpha-1 proteinase inhibitor launch should ease ongoing supply pressures on Bayer's Prolastin

Related Content

UsernamePublicRestriction

Register

PS041013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel